Based on the promising adjuvant properties comparable to most widely used adjuvants Alum and Quillaja saponins (including QS-21), our team has decided to carry out advance studies to develop Astragaloside VII (AST VII) as a new vaccine adjuvant and/or an immunotherapeutic agent. To do so, one of the most important steps is establishing efficient isolation and purification processes to obtain AST VII at large scale. In this thesis, starting from laboratory scale to semi-pilot scale, it was aimed to optimize the production steps of AST VII from Astragalus trojanus. Factor screening (1 categorical and 3 numerical) and optimization studies were performed using experimental design, based on which methanol (MeOH) as solvent, 1:20 (g/mL) as plant:solvent ratio, 0.5-1.0 mm as plant particle size and 8-10 hours for extraction time were selected yielding 0.36 percent g AST VII/g plant. To enrich AST VII in extract, pre-purification studies were performed such as liquid-liquid extraction, resin fractionation and precipitation. The results showed that the resin (D-101) fractionation employing water, 20 percent EtOH and EtOH was superior. To enrich AST VII up to 85-90 percent purity, several chromatographic steps using normal (employing EtOAc:MeOH:Water and Chloroform:MeOH:Water systems) and reversed phase (C18; employing MeOH:Water systems) silica gel were used. In last step, a precipitation method was developed using MeOH and acetone affording 98 percent purity. Developed method at lab scale (3.5 g) was successfully transferred to semi-pilot scale (about 100 g) with minor modifications, and a crucial step towards large-scale isolation (kg) of AST VII was accomplished.